Ocera Therapeutics Rises on Positive Results
24/7 Wall St. By Chris Lange
For some background: OCR-002 is an ammonia scavenger and has been granted orphan drug designation
and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease
Chimerix(NASDAQ: CMRX) “remains committed to better understanding the full data set as we consider potential paths forward for brincidofovir.” Currently Chimerix has a strong cash position and leadership team
wow, grabbed some.
$8 green tomorrow
where alot of companys lose money FIT makes big profits
Investor Business Daily
Solar Tax Extensions
January 26, 2016 9:32 pm
Apple’s iPhone growth era comes to an end
Tim Bradshaw in San Francisco
What makes Anavex such an exciting story is the Company is not focused on treating the symptoms of Alzheimer’s but rather is focused on the root cause which is believed to be protein misfolding. AVXL’s Anavex 2-73 can work as an agonist for the sig-1R receptor that is behind protein misfolding. What is even more exciting is the fact that the same mechanism can work in Parkinson’s and Huntington diseases.
AVXL lead drug candidates, Anavex 2-73 and Anavex PLUS, a combination of Anavex 2-73 and donepezil (Aricept®) are currently being evaluated in a Phase 2a clinical trial for Alzheimer’s disease and continue to be the major catalyst here.
In earlier preclinical studies, Anavex 2-73 showed potential to halt and/or reverse Alzheimer’s disease.Additionally, positive preclinical data reveals the potential for Anavex 2-73 as a platform drug to treat additional CNS disorders, including epilepsy.
Anavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA
Anavex Life Sciences Corp.
NEW YORK, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program for ANAVEX 2-73. Guidance received from the FDA confirms the Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial.
“Working with a highly vulnerable patient population, the Company is proceeding in a rational, step-wise process. Armed with the necessary data from the Phase 2a study to optimally design future trials, we lookforward to expanding our development program,” said Kristina M. Capiak, Vice President Regulatory Affairs of Anavex.
Valuation should be every bit of $150+ and that doesn't include how fast sales are accelerating
Sentiment: Strong Buy
FIT Earnings Date
Earnings announcement* for FIT: Feb 01, 2016
Fitbit, Inc. to report earnings on 02/01/2016.
Ackman's fund sells 5 million Valeant shares
Reuters38 minutes ago